1 Department of Neurosurgery, Harrison International Peace Hospital affiliated to Hebei Medical University, Hengshui, China.
2 Department of Pathology, Harrison International Peace Hospital affiliated to Hebei Medical University, Hengshui, China.
Cancer Biother Radiopharm. 2019 Feb;34(1):1-6. doi: 10.1089/cbr.2018.2589. Epub 2019 Jan 24.
To investigate the expression levels of matrix metalloproteinases-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in pituitary adenomas (PAs), and to analyze the relationship of the expressions of the two with the prognosis of patients.
A total of 108 patients with PAs diagnosed in our hospital from May 2010 to May 2012 were selected and divided into the invasive PA (IPA) group (n = 58) and the non-IPA group (n = 50) according to the invasiveness of PAs. Hematoxylin and eosin (H&E) staining was used to observe the pathological state of patients. The expression levels of MMP-9 and TIMP-1 were measured by immunohistochemistry and western blotting at protein level and reverse transcription-polymerase chain reaction at gene level, respectively. The expression levels of MMP-9 and TIMP-1 in serum of patients before operation were tested using enzyme-linked immunosorbent assay, and patients with PAs after operation were followed up.
The positive expression rate of MMP-9 in IPAs was significantly higher than that in non-IPAs, whereas that of TIMP-1 was relatively high in non-IPAs, and the differences were statistically significant (p < 0.05). At both protein and gene levels, MMP-9 was highly expressed in IPAs, whereas TIMP-1 was highly expressed in non-IPAs, and the differences were statistically significant (p < 0.05 in all comparisons). Before operation, the expression level of MMP-9 in serum of patients with IPAs was relatively high, whereas that of TIMP-1 in serum of patients with non-IPAs was relatively high, and the differences were statistically significant (p < 0.05 in all comparisons).
The postoperative survival rate of patients with highly expressed MMP-9 was relatively low, whereas that of patients with highly expressed TIMP-1 was relatively high. The abnormal expressions of MMP-9 and TIMP-1 play important roles in the invasion process of PAs. The prognoses of patients with low expression MMP-9 and high expression TIMP-1 are more positive.
研究基质金属蛋白酶-9（MMP-9）和金属蛋白酶组织抑制剂-1（TIMP-1）在垂体腺瘤（PA）中的表达水平，并分析两者的表达与患者预后的关系。
选取我院 2010 年 5 月至 2012 年 5 月收治的 108 例 PA 患者，根据肿瘤的侵袭性分为侵袭性 PA（IPA）组（n=58）和非 IPA 组（n=50）。采用苏木精-伊红（H&E）染色观察患者的病理状态。采用免疫组织化学和 Western blot 法分别在蛋白水平和逆转录-聚合酶链反应（RT-PCR）法在基因水平检测 MMP-9 和 TIMP-1 的表达水平。采用酶联免疫吸附试验检测患者术前血清中 MMP-9 和 TIMP-1 的表达水平，对术后 PA 患者进行随访。
IPA 组 MMP-9 的阳性表达率明显高于非 IPA 组，而 TIMP-1 的阳性表达率则相对较高，差异均有统计学意义（p<0.05）。在蛋白和基因水平上，IPA 组 MMP-9 高表达，而非 IPA 组 TIMP-1 高表达，差异均有统计学意义（p<0.05）。术前 IPA 组患者血清 MMP-9 表达水平相对较高，而非 IPA 组患者血清 TIMP-1 表达水平相对较高，差异均有统计学意义（p<0.05）。
MMP-9 高表达患者的术后生存率相对较低，而 TIMP-1 高表达患者的术后生存率相对较高。MMP-9 和 TIMP-1 的异常表达在 PA 的侵袭过程中发挥重要作用。MMP-9 低表达、TIMP-1 高表达患者的预后更积极。
